Tyler has been building a career in the commercial development area of the pharmaceutical industry, and has long been intrigued by the intersection of science and business. In his current role, he leads a team that evolves the Bristol Myers Squibb cell therapy strategy from both the internal as well as the external business development perspective, and provides commercial representation to the pipeline of cell therapy programs in development.
Prior to joining the cell therapy organization, Tyler held roles in the BMS’ worldwide commercial oncology team during the launch and growth of several transformational immuno-oncology drugs. Before joining BMS, Tyler was in business development at AstraZeneca where he contributed to the search, evaluation, and negotiation of transactions across therapeutic areas. Previously, he was in a corporate strategy role at MedImmune ahead of the integration with AstraZeneca. Tyler has also held positions at a life sciences management consulting firm, a biotech startup, and his early career was in the finance industry. Tyler has a degree in economics and biology from Wake Forest University and an MBA from Harvard Business School.